<DOC>
	<DOCNO>NCT00387933</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate , vatalanib , hydroxyurea may stop growth tumor cell block enzymes need cell growth . Vatalanib may also stop growth tumor cell block blood flow tumor . Giving imatinib mesylate vatalanib together hydroxyurea may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate vatalanib give together hydroxyurea treat patient recurrent relapse malignant glioma .</brief_summary>
	<brief_title>Imatinib Mesylate , Vatalanib , Hydroxyurea Treating Patients With Recurrent Relapsed Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity imatinib mesylate vatalanib administer hydroxyurea patient recurrent relapse grade 3 4 malignant glioma . - Determine safety tolerability regimen patient . - Determine single-dose repeated-dose pharmacokinetic profile imatinib mesylate ( serum ) vatalanib patient . - Determine pre- post-treatment antiangiogenic effect regimen patient , use dynamic contrast-enhanced MRI evaluate change extent vascular permeability , perfusion , relative tumor blood volume . - Determine whether change diffusion-weighted image MRI ( quantitated apparent diffusion coefficient map ) correlate tumor cellularity tumor cell death patient treat regimen . - Determine antitumor activity regimen , term radiographic response , progression-free survival , overall survival , patient . OUTLINE : This open-label , dose-escalation study imatinib mesylate vatalanib . Patients receive oral vatalanib daily , oral imatinib mesylate daily , oral hydroxyurea twice daily day 1-28* . Treatment repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Patients receive vatalanib alone daily day 1-7 follow vatalanib , imatinib mesylate , hydroxyurea day 8-35 course 1 . Cohorts 3-6 patient receive escalate dos imatinib mesylate vatalanib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . After completion study treatment , patient evaluate 28 day . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Grade 3 4 disease In first , second , third recurrence relapse Multifocal disease allow PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 12 week Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 9 g/dL Platelet count &gt; 100,000/mm^3 Potassium normal* Total calcium ( correct ) normal* Magnesium normal* Phosphorus normal* aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Negative proteinuria dipstick OR total urinary protein ≤ 500 mg creatinine clearance ≥ 50 mL/min 24hour urine collection Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No acute chronic liver renal disease leave ventricular ejection fraction ( LVEF ) ≥ 45 % Multi Gated Acquisition Scan ( MUGA ) echocardiogram No complete leave bundle branch block No obligate use cardiac pacemaker No congenital long QT syndrome No history current ventricular atrial tachyarrhythmias No clinically significant rest bradycardia ( i.e. , heart rate &lt; 50 beats/minute ) No right bundle branch block leave anterior hemiblock ( bifascicular block ) No uncontrolled hypertension ≥ grade 2 , history labile hypertension , history poor compliance antihypertensive regimen No concurrent unstable angina pectoris angina pectoris within past 3 month No congestive heart failure ( CHF ) No history CHF arrhythmia require concurrent digoxin verapamil No acute myocardial infarction within past 3 month No impaired cardiac function clinically significant cardiac disease No peripheral neuropathy ≥ grade 2 No unresolved diarrhea ≥ grade 2 No uncontrolled diabetes No active uncontrolled infection require intravenous antibiotic No impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption vatalanib , hydroxyurea , and/or everolimus , include follow : Ulcerative disease Uncontrolled nausea , vomit , diarrhea Malabsorption syndrome Small bowel resection No concurrent severe and/or uncontrolled medical condition would preclude study participation compliance No known HIV positivity No primary malignancy clinically significant require active intervention NOTE : *Supplement allow PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior tumor biopsy ( 4 week since prior surgical resection ) Prior polifeprosan 20 carmustine implant ( Gliadel® wafer ) allow discretion principal investigator Prior hydroxyurea allow More 4 week since prior chemotherapy ( 6 week nitrosoureas 1 week metronomicdosed chemotherapy [ e.g. , daily etoposide hydrochloride cyclophosphamide ] ) recover More 4 week since prior radiotherapy recover More 2 week since prior immunotherapy recover More 4 week since prior investigational drug recover No prior plateletderived growth factor vascular endothelial growth factordirected therapy More 2 week since prior hematopoietic colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ Granulocytemacrophage colonystimulating factor ( GMCSF ) ] ) Prior epoetin alfa allow No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>